Combineering:
from lab result to exit-ready.
A systems pathway for de-risking diagnostics and building platform revenue, developed for university and research institution technology portfolios. Complementary technologies are combined and staged through validation gates, so every go/no-go decision rests on a number rather than a judgment call.
Layering imaging and molecular data lifts predictive accuracy from 0.62 to 0.93, clearing the threshold used as the go/no-go gate in both validation phases. Source: Permuth et al., Oncotarget 2016.
Two engines, one system: a staged validation pipeline that de-risks diagnostics toward exit, and a platform CRO that generates revenue today.
What is Combineering?
The deliberate integration of complementary technologies, staged through built-in validation gates, to convert promising science into predictable, fundable outcomes.
Reduces risk
Quantitative gates replace gut-feel go/no-go decisions at every stage of development.
Repeatable playbook
One validated pathway that future faculty spinouts can reuse rather than reinvent.
Near-term revenue
Platform services generate income while diagnostics mature toward acquisition.
Four strategies that make the pathway work.
These principles hold constant across every technology run through the model.
Technology integration
Combine vertical technologies along the standard-of-care continuum.
- Improve sensitivity and specificity
- Fits where clinicians already make decisions
Cross-disciplinary collaboration
Validate technologies through cross-pollination across disciplines.
- Engineering, biology, and chemistry in one loop
- Independent confirmation before scale-up
Platform assays
Build assays that measure performance across many compounds.
- Bioabsorbability and toxicity
- Cardiotoxicity screening
Natural product engineering
Partner with biologists and chemists on natural source chemistry.
- Analogs and derivatives
- Plant-based production routes
Two pathways, one system.
Combineering operationalizes through two complementary engines, each producing a different kind of asset.
-
1
Diagnostic de-risking flow
A staged validation pipeline that moves a faculty-founded diagnostic from single-site proof of concept to multi-site, system-wide replication, generating an objective, data-driven exit decision. The asset is a company built for acquisition or merger.
-
2
Platform technology CRO
A portfolio of hosted platform technologies offered fee-for-service in a contract research model, either as a spinout asset or as an institutional core service. The asset is recurring revenue, available today.
Revenue now, exit value later.
Most university technologies are asked to prove themselves on a single timeline. Running both engines at once funds the slower one.
- Phase 1: single-site CLIA validation
- Phase 2: multi-site replication
- Outcome: exit-ready company
- In parallel: fee-for-service platform income
The diagnostic de-risking flow.
Each phase must clear an objective AUC gate before it advances.
Single-site validation
CLIA-certified setting. Tests algorithm robustness against real clinical samples and workflow.
Multi-site replication
Deployed across multiple health systems to confirm robustness at scale.
Exit-ready company
Validated at scale and positioned for acquisition or merger.
If AUC falls below 0.9 at either gate, the program pauses for algorithm refinement before re-testing. That protects investors and the institution from premature scale-up.
Four effects of gating the pipeline.
An objective gate, not a judgment call
AUC of 0.9 or better is a quantitative, pre-agreed threshold that removes ambiguity from every go/no-go decision.
Real clinical workflow from day one
CLIA-setting validation confirms the algorithm performs outside the research lab.
Commercial-scale proof inside a trusted system
Multi-site deployment mirrors a national rollout within a trusted network of health systems.
Every gate cleared raises the valuation
Each successful phase is a milestone acquirers and investors recognize, compounding company value toward exit.
Five diagnostics, placed along existing care pathways.
Combineering does not ask clinicians to change how they work. Each technology slots into a decision point that already exists.
Prostate cancer
-
1
Radiomics-based imaging diagnostic
Precise habitat mapping for prostate cancer.
-
2
Computational diagnostic
Predicts response and treatment regimens.
-
3
Liquid biopsy PCR assay
Predicts drug resistance.
Pancreatic cysts
-
1
Liquid biopsy assay
Early detection of asymptomatic pancreatic cysts.
-
2
Combined radiomics and liquid biopsy diagnostic
Early detection integrating MRI radiomics for IPMN evaluation.
Both integrate at the risk-assessment step, with the goals of reducing unnecessary resections, enabling intervention before malignancy, and lowering cost of care.
Clinical accuracy alone does not secure reimbursement.
A commercialized pancreatic cyst molecular test already exists in the market, which is proof that demand for this category is real. Yet similar molecular cyst tests have been classified by some payers as investigational and not medically necessary, limiting reimbursement despite clinical validity.
Staged, multi-site, AUC-gated validation is what builds the evidence record that payers and acquirers actually require.
Build the evidence record before you need it.
- Market demand is established
- Clinical validity is not sufficient
- Multi-site evidence changes the conversation
The platform technology CRO.
Platform capabilities hosted in the university incubator and offered fee-for-service, revenue-generating from day one. Each platform can become founding IP for a startup raising outside capital, or remain a shared core facility billing internal and external researchers.
GPCR platform technologies
Hit-to-lead screening for GPCR-active small molecules, supporting early-stage drug discovery programs.
AAV closed-loop manufacturing
End-to-end viral vector production for gene therapy pipelines, from design through release.
Low-resource biomanufacturing
Walnut transgenic embryo plants engineered to produce natural dyes, melanin, and dopamine.
Already running
A drug testing hub already connects a diabetes and Alzheimer's rat model, enteroid organoid work, and cardiotoxicity assays including bio-imprinted pacemaker cells. An industry partner supplies compounds fee-for-service alongside integration of institutional IP. That hub-and-spoke arrangement is the template the three new platforms are built to replicate.
Open considerations: patient data consent forms and CLIA laboratory-developed test requirements.
Why a research university is the right host.
The pathway assumes four institutional assets. The strongest host institutions already have all four in place.
CLIA-certified infrastructure
On-campus clinical-grade testing to launch Phase 1 validation without external partners.
A built-in multi-site network
An affiliated health system network that already spans the sites Phase 2 requires.
Agricultural and plant biology strength
A natural home for transgenic plant manufacturing platforms most institutions cannot offer.
Cross-disciplinary faculty
Engineering, biology, and chemistry collaborators already validating across these platforms.
Combineering = predictability + collaboration + practical validation.Innovation happens where disciplines meet
Three actions to put the pathway to work.
What the framework needs from institutional leadership in order to run this year.
Formalize the CLIA-to-multi-site pipeline as a standard milestone framework for university spinouts.
Allocate incubator space and seed support to launch the platform CRO services.
Identify one or two pilot faculty technologies to run through the Combineering pathway this year.
How the presentation evolved.
The same science, rebuilt as an institutional pitch six months later.
Original working deck
Combineering.pptx
- Concept and strategies, then straight into clinical material
- Clinical content carried largely as screenshots and diagrams
- Collaborator names listed without surrounding structure
- Closes on a definition rather than a request
June 2026 final
Combineering_NEW_June_2026_Final.pptx
- Agenda, section dividers, running footer, slide numbering
- Clinical content rebuilt as native flow diagrams and a native chart
- Collaborators framed as an active validation network
- Closes on three specific requests to leadership
| What changed | Effect on the argument |
|---|---|
| Two named pathways | Diagnostic de-risking and the platform CRO separate into distinct engines, one aimed at exit value and one at revenue available today. |
| Explicit AUC gates | The 0.9 threshold becomes a pre-agreed decision rule at both phases, with a stated pause-and-refine path when it is missed. |
| Payer-grade validation | New material notes that comparable molecular cyst tests have been treated by some payers as investigational, making the case that accuracy alone does not secure reimbursement. |
| Institutional fit section | Four concrete reasons this specific institution can run the pathway. |
| A defined ask | The deck ends with three actions for leadership instead of a summary statement. |
Slide index.
Contents of each file, in order.
Combineering.pptx
- Title slide
- What is Combineering?
- Combineering key strategies
- Prostate cancer section title
- Imaging diagram
- Diagnostic interface graphic
- Prostate cancer diagnosis and treatment continuum
- Radiomic and genomic data for IPMN pathology
- Clinical management of pancreatic cysts
- Radiogenomic impact and clinical utility AUC series
- Commercial molecular cyst test reference
- Cross-pollination and validation
- Platform technologies
- Driving collaborations
- Key takeaways
- Closing graphic
Combineering_NEW_June_2026_Final.pptx
- Title slide
- Agenda
- What is Combineering?
- Key strategies
- Two pathways, one system
- Section: Pathway 1
- The diagnostic de-risking flow
- Why this de-risks the company
- Case study: prostate cancer
- Case study: pancreatic cysts
- The Combineering effect on accuracy chart
- Why payer-grade validation matters
- Section: Pathway 2
- The platform technology CRO model
- Cross-pollination and validation network
- Active collaboration: drug testing
- Driving collaborations: biology and industry
- Three new platforms ready to scale
- Why the host institution is positioned to lead
- Key takeaways and the ask
Running a technology through a pathway like this?
The Venture Bench builds the funding strategy, leadership team, and operating systems that carry a scientific breakthrough from validation to acquisition.
Talk to our team